Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Patheon Will Acquire API Producer Irix

by Michael McCoy
March 9, 2015 | A version of this story appeared in Volume 93, Issue 10

The drug services firm Patheon has agreed to acquire the pharmaceutical chemical maker Irix Pharmaceuticals for an undisclosed sum. Founded in 1996 by former Roche executives, Irix produces active pharmaceutical ingredients (APIs), including highly potent and controlled substances, in Greenville and Florence, S.C. Following a merger last year with DSM’s fine chemicals business, Patheon operates former DSM API facilities in Regensburg, Germany, and Linz, Austria. Patheon executive Lukas Utiger says the Irix acquisition will add API capacity in the U.S.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.